- Home
- ERAS vs UROY Comparison
ERAS vs UROY Comparison
Compare ERAS & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- UROY
- Stock Information
- Founded
- ERAS 2018
- UROY 2017
- Country
- ERAS United States
- UROY Canada
- Employees
- ERAS 129
- UROY N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- UROY
- Sector
- ERAS Health Care
- UROY
- Exchange
- ERAS Nasdaq
- UROY Nasdaq
- Market Cap
- ERAS 413.6M
- UROY 336.8M
- IPO Year
- ERAS 2021
- UROY N/A
- Fundamental
- Price
- ERAS $1.42
- UROY $2.49
- Analyst Decision
- ERAS Strong Buy
- UROY Strong Buy
- Analyst Count
- ERAS 6
- UROY 2
- Target Price
- ERAS $4.83
- UROY $4.00
- AVG Volume (30 Days)
- ERAS 1.1M
- UROY 3.2M
- Earning Date
- ERAS 08-11-2025
- UROY 07-23-2025
- Dividend Yield
- ERAS N/A
- UROY N/A
- EPS Growth
- ERAS N/A
- UROY N/A
- EPS
- ERAS N/A
- UROY N/A
- Revenue
- ERAS N/A
- UROY $15,984,827.00
- Revenue This Year
- ERAS N/A
- UROY N/A
- Revenue Next Year
- ERAS N/A
- UROY N/A
- P/E Ratio
- ERAS N/A
- UROY N/A
- Revenue Growth
- ERAS N/A
- UROY N/A
- 52 Week Low
- ERAS $1.01
- UROY $1.43
- 52 Week High
- ERAS $3.45
- UROY $3.12
- Technical
- Relative Strength Index (RSI)
- ERAS 53.15
- UROY 52.22
- Support Level
- ERAS $1.42
- UROY $2.29
- Resistance Level
- ERAS $1.58
- UROY $2.54
- Average True Range (ATR)
- ERAS 0.10
- UROY 0.11
- MACD
- ERAS 0.01
- UROY -0.02
- Stochastic Oscillator
- ERAS 68.65
- UROY 41.18
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.